Cargando…

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

BACKGROUND: To date, the cornerstone of treatment in patients with advanced or metastatic cholangiocarcinoma (CCA) is systemic chemotherapy based on a combination of gemcitabine and a platinum derivative. Other therapeutic approaches including targeted agents and tyrosine kinase inhibitors (TKI) hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moehler, Markus, Maderer, Annett, Ehrlich, Anne, Foerster, Friedrich, Schad, Arno, Nickolay, Tanja, Ruckes, Christian, Weinmann, Arndt, Sivanathan, Visvakanth, Marquardt, Jens U., Galle, Peter Robert, Woerns, Marcus, Thomaidis, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330479/ https://www.ncbi.nlm.nih.gov/pubmed/30634942 http://dx.doi.org/10.1186/s12885-018-5223-7

Ejemplares similares

Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial
por: Thomaidis, Thomas, et al.
Publicado: (2014)

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
por: Thomaidis, Thomas, et al.
Publicado: (2014)

The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
por: Michel, Maurice, et al.
Publicado: (2021)

Advances in the endoscopic management of malignant biliary obstruction
por: Thomaidis, Thomas, et al.
Publicado: (2020)

Evaluation of novel LCI CAD EYE system for real time detection of colon polyps
por: Neumann, Helmut, et al.
Publicado: (2021)

Sonographic assessment of low muscle quantity identifies mortality risk during COVID‐19: a prospective single‐centre study
por: Kremer, Wolfgang M., et al.
Publicado: (2021)

The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma
por: Gairing, Simon Johannes, et al.
Publicado: (2021)

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
por: Thol, Felix, et al.
Publicado: (2021)

Evaluation of a novel colonoscope offering flexibility adjuster – a retrospective observational study
por: Gerges, Christian, et al.
Publicado: (2021)

Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases
por: Desuki, Alexander, et al.
Publicado: (2019)

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort
por: Huber, Yvonne, et al.
Publicado: (2018)

No Evidence for Classic Thrombotic Microangiopathy in COVID-19
por: Falter, Tanja, et al.
Publicado: (2021)

Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report
por: Sprinzl, Martin F, et al.
Publicado: (2006)

Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy
por: Wehler, Thomas C., et al.
Publicado: (2012)

In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma
por: Xue, Cong, et al.
Publicado: (2016)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

Randomized Comparison of Selective Internal Radiotherapy (SIRT) Versus Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) for the Treatment of Hepatocellular Carcinoma
por: Pitton, Michael B., et al.
Publicado: (2014)

Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients
por: Haupts, Anna, et al.
Publicado: (2021)

Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial
por: Kloeckner, Roman, et al.
Publicado: (2014)

Transjugular Portosystemic Stent Shunt: Impact of Right Atrial Pressure on Portal Venous Hemodynamics Within the First Week
por: Pitton, Michael Bernhard, et al.
Publicado: (2021)

Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
por: Roehlen, Natascha, et al.
Publicado: (2023)

Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
por: Grimm, Daniel, et al.
Publicado: (2016)

Medication adjustment of afatinib and combination therapy with sitagliptin for alleviating afatinib-induced diarrhea in rats
por: Zhang, Li, et al.
Publicado: (2023)

Diabetes mellitus and its impact on mortality rate and outcome in pulmonary embolism
por: Schmitt, Volker H, et al.
Publicado: (2021)

Diabetes Mellitus and Its Association with Adverse In-Hospital Outcomes in Patients with COVID-19—A Nationwide Study
por: Schmitt, Volker H., et al.
Publicado: (2023)

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
por: Wind, Sven, et al.
Publicado: (2016)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
por: Huang, Chun-Yao, et al.
Publicado: (2023)

Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma
por: Kloeckner, Roman, et al.
Publicado: (2015)

Young-onset gastric cancer and Epstein–Barr Virus (EBV) – a major player in the pathogenesis?
por: Moore, Assaf, et al.
Publicado: (2020)

Obesity and Its Impact on Adverse In-Hospital Outcomes in Hospitalized Patients With COVID-19
por: Keller, Karsten, et al.
Publicado: (2022)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: Chen, You-Yi, et al.
Publicado: (2021)

“Liquid elbows” due to afatinib administration
por: Zarogoulidis, Paul, et al.
Publicado: (2017)

Baseline Splenic Volume Outweighs Immuno-Modulated Size Changes with Regard to Survival Outcome in Patients with Hepatocellular Carcinoma under Immunotherapy
por: Müller, Lukas, et al.
Publicado: (2022)

Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates
por: Müller, Lukas, et al.
Publicado: (2023)

Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence: potential implications for salvage liver transplantation?
por: Heinrich, Stefan, et al.
Publicado: (2022)

Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China
por: You, Ruxu, et al.
Publicado: (2019)

A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer
por: Doval, D C, et al.
Publicado: (2004)

Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma
por: Weinmann, Arndt, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_0c8u2hf73734k1shu3747ob7uf